bismuth + proton pump inhibitor

This entry refers to the combination of a bismuth compound (such as bismuth subcitrate or bismuth subsalicylate) and a proton pump inhibitor (PPI, such as omeprazole, lansoprazole, pantoprazole, rabeprazole, or esomeprazole). This combination is a core component of "bismuth quadruple therapy," which is primarily used for the eradication of Helicobacter pylori infection. The regimen typically also includes two antibiotics (commonly metronidazole and tetracycline or amoxicillin), but the specific request here is for the dual combination. Bismuth compounds act by disrupting bacterial cell walls and providing mucosal protection in the stomach lining. Proton pump inhibitors suppress gastric acid secretion by inhibiting H+/K+ ATPase in gastric parietal cells, creating an environment less favorable for H. pylori survival and enhancing antibiotic efficacy[1][2][4]. This dual therapy alone is not standard; it serves as part of multi-drug regimens.